34P Updated Data from Beamion LUNG-1, a Phase (ph) Ia/b Trial of the HER2-specific Tyrosine Kinase Inhibitor (TKI), Zongertinib (BI 1810631), in Patients (pts) with HER2 Mutation-Positive (m+) NSCLC
ESMO Open（2024）
Key words
Biomarker Analysis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined